Neutralization of endotoxin in vitro and in vivo by a human lactoferrin- derived peptide

Infection and Immunity

Volumn 67, Issue 3, 1999, Pages 1353-1358

  Zhang, Gui Hang ^a,b   Mann, David M ^b,c   Tsai, Chao Ming ^a  

^a CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^b HOLLAND LABORATORY   (United States)

^c GEORGE WASHINGTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTOXIN; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; LACTOFERRIN; LF 33; SYNTHETIC PEPTIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANIMAL MODEL; ARTICLE; BACTERIAL VIRULENCE; BLOOD CLOTTING; CONCENTRATION RESPONSE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; ENDOTOXEMIA; ESCHERICHIA COLI; INTRAVENOUS DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEPTIC SHOCK;

EID: 0032975547     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.67.3.1353-1358.1999     Document Type: Article

References (44)

1. Appelmelk, B. J., Y.-Q. An, M. Geerts, B. G. Thijs, H. A. DeBoer, D. M. MacLaren, J. DeGraaff, and J. H. Nuijens. 1994. Lactoferrin is a lipid A-binding protein. Infect. Immun. 62:2628-2632.
2. Bellamy, W., M. Takase, K. Yamauchi, H. Wakabayashi, K. Kawase, and M. Tomita. 1992. Identification of the bactericidal domain of lactoferrin. Biochim. Biophys. Acta 1121:130-136.
3. Beutler, B., and A. Cerami. 1988. Tumor necrosis, cachexia, shock, and inflammation: a common mediator. Annu. Rev. Biochem. 57:505-518.
4. Cooperstock, M. S. 1974. Inactivation of endotoxin by polymyxin B. Antimicrob. Agents Chemother. 6:422-425.
5. Demistri, M. T., M. Velucchi, L. Bracci, A. Rustici, M. Porro, P. Villa, and P. Ghezzi. 1996. Inhibition of LPS-induced systemic and local TNF production by a synthetic anti-endotoxin peptide (SAEP-2). J. Endotoxin Res 3: 445-454.
6. Elass-Rochard, E., A. Roseanu, D. Legrand, M. Trif, V. Salmon, C. Motas, J. Montreuil, and G. Spik. 1995. Lactoferrin-lipopolysaccharide interaction: involvement of the 28-34 loop region of human lactoferrin in the high-affinity binding to Escherichia coli O55:B5 lipopolysaccharide. Biochem. J. 312:839-845.
7. Elass-Rochard, E., D. Legrand, V. Salmon, A. Roseanu, M. Trif, P. S. Tobias, J. Mazurier, and G. Spik. 1998. Lactoferrin inhibits the endotoxin interaction with CD14 by competition with the lipopolysaccharide-binding protein. Infect. Immun. 66:486-491.
8. Emancipator, K., G. Csako, and R. J. Elin. 1992. In vivo inactivation of bacterial endotoxin by human lipoproteins and apolipoproteins. Infect. Immun. 60:596-601.
9. Evans, M. E., and M. Pollack. 1993. Effect of antibiotic class and concentration on the release of lipopolysaccharide from Eschcrichia coli. J. Infect Dis. 167:1336-1343.
10. Fisher, C. J., M. N. Marra, J. E. Palardy, C. R. Marchbanks, R. W. Scott, and S. M. Opal. 1994. Human neutrophil bactericidal/permeability-increasing protein reduces mortality rate from endotoxin challenge: a placebo-controlled study. Crit. Care Med. 22:553-558.
11. Freudenberg, M. A., and C. Galanos. 1991. Tumor necrosis factor alpha mediates lethal activity of killed gram-negative and gram-positive bacteria in D-galactosamine-treated mice. Infect. Immun. 59:2110-2115.
12. Galanos, C., M. A. Freudenberg, and W. Reutter. 1979. Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc. Natl. Acad. Sci. USA 76:5939-5943.
13. Gough, M., R. E. W. Hancock, and N. M. Kelly. 1996. Antiendotoxin activity of cationic peptide antimicrobial agents. Infect. Immun. 64:4922-4927.
14. Heumann, D., D. Le Roy, and M. P. Glauser. 1996. Contribution of TNF and of LPS in endotoxemic shock in mice: a reappraisal. J. Endotoxin Res 3:87-92.
15. Iwanaga, S., T. Miyata, F. Tokunaga, and T. Muta. 1992. Molecular mechanism of hemolymph clotting system in Limulus. Thromb. Res. 68:1-32.
16. Jeremy, B. 1995. Lactoferrin: a multifunctional immunoregulatory protein? Immunol. Today 16:417-419.
17. Kelly, N. M., L. Young, and A. Cross. 1991. Differential induction of tumor necrosis factor by bacteria expressing rough and smooth lipopolysaccharide phenotypes. Infect. Immun. 59:4491-4496.
18. Larrick, J. W., M. Hirata, R. F. Balint, J. Lee, J. Zhong, and S. C. Wright. 1995. Human CAP18: a novel antimicrobiol lipopolysaccharide-binding protein. Infect. Immun. 63:1291-1297.
19. Lonnerdal, B., and S. Iyer. 1995. Lactoferrin: molecular structure and biological function. Annu. Rev. Nutr. 15:93-110.
20. Mann, D. M., E. Romm, and M. Migliorini. 1994. Delineation of the glycosaminoglycan-binding site in the human inflammatory response protein lactoferrin. J. Biol. Chem. 269:23661-23667.
21. 20a. Mann, D. M., et al. Submitted for publication.
22. Marra, M. N., M. B. Thornton, J. L. Snable, C. G. Wilde, and R. W. Scott. 1994. Endotoxin-binding and -neutralizing properties of recombinant bactericidal/permeability-increasing protein and monoclonal antibodies HA-1A and E5. Crit. Care Med. 22:559-565.
23. Mathison, J. C., P. S. Tobias, E. Wolfson, and R. J. Ulevitch. 1992. Plasma LPS-binding protein, a key component in macrophage recognition of gram-negative LPS. J. Immunol. 194:200-206.
24. Mattsby-Baltzer, I., A. Roseanu, C. Motas, J. Elverfors, I. Engberg, and L. A. Hanson. 1996. Lactoferrin or a fragment thereof inhibits the endotoxin-induced interleukin-6 response in human monocytic cells. Pediatr. Res. 40: 257-262.
25. Mosmann, T. 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assay. J. Immunol. Methods 65: 55-63.
26. 106-138-immunoglobulin G in whole blood. Infect. Immun. 65:2160-2167.
27. Parrillo, J. E. 1996. Shock syndromes related to sepsis, p. 496-501. In J. C. Bennett and F. Plum (ed.), Cecil textbook of medicine, 20th ed. The W. B. Saunders Co., Philadelphia, Pa.
28. Poolman, J. T. 1995. Development of a meningococcal vaccine. Infect. Agents Dis. 4:13-28.
29. Reid, C., C. Wahl, T. Miethke, G. Wellnhofer, C. Landgraft, J. Schneider-Mergener, and A. Hoess. 1996. High affinity endotoxin-binding and neutralizing peptides based on the crystal structure of recombinant Limulus antilipopolysaccharide factor. J. Biol. Chem. 271:28120-28127.
30. Rietschel, E. T., T. Kirikae, F. U. Schade, A. J. Ulmer, O. Holst, H. Brade, G. Schmidt, U. Mamat, H.-D. Grimmecke, S. Kusumoto, and U. Zaahringer. 1993. The chemical structure of bacterial endotoxin in relation to bioactivity. Immunobiology 187:169-190.
31. Rietschel, E. T., H.-W. Wollenweber, H. Brade, U. Zaahringer, B. Lindner, U. Seydel, H. Bradaczek, G. Barnickel, H. Labischinski, and P. Giesbrecht. 1984. Structure and conformation of the lipid A component of lipopolysaccharides, p. 187-220. In E. T. Rietschel (ed.), Handbook of endotoxin, vol. 1. Chemistry of endotoxin. Elsevier Science Publishers B. V., New York, N.Y.
32. Rosenstreich, D. L., and S. N. Vogel. 1980. Central role of macrophages in the host response to endotoxin, p. 11-15. In D. Schlessinger (ed.), Microbiology-1980. American Society for Microbiology, Washington, D.C.
33. Ruff, M. R., and G. E. Gifford. 1981. Tumor necrosis factor. Lymphokines 2: 235-272.
34. Rustici, A., M. Velucchi, R. Faggioni, M. Sironi, P. Ghezzi, S. Quataert, B. Green, and M. Porro. 1993. Molecular mapping and detoxification of the lipid A binding site by synthetic peptides. Science 259:361-365.
35. Schumann, R. R. 1992. Function of LPS-binding protein (LBP) and CD14, the receptor for LPS/LBP complex: a short review. Res. Immunol. 143:11-15.
36. Shenep, J. L., R. P. Barton, and K. A. Mogan. 1985. Role of antibiotic class in the rate of liberation of endotoxin during therapy for experimental gram-negative bacterial sepsis. J. Infect. Dis. 151:1012-1018.
37. Tanamoto, K.-I. 1997. Novel strategies to attenuate the effect of lipopolysaccharide on the immune response. Curr. Opin. Infect. Dis. 10:177-182.
38. Trumpler, U., P. W. Straub, and A. Rosemund. 1989. Antibacterial prophylaxis with lactoferrin in neutropenic patients. Eur. J. Clin. Microbiol. Infect. Dis. 8:310-313.
39. Ulevitch, R. J., and P. S. Tobias. 1995. Receptor-dependent mechanisms of cell stimulation by bacterial endotoxin. Annu. Rev. Immunol. 13:437-457.
40. 5 of human lactoferrin is essential for binding to heparin, bacterial lipopolysaccharide, human lysozyme and DNA. Biochem. J. 328:145-151.
41. Verhoef, J., W. M. N. Hustinx, H. Frasa, and A. I. M. Hoepelman. 1996. Issues in the adjunct therapy of severe sepsis. J. Antimicrob. Chemother. 38: 167-182.
42. Warren, H. S., S. F. Amato, C. Fitting, K. M. Black, P. M. Loiselle, M. S. Pasternack, and J.-M. Cavaillon. 1993. Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide. J. Exp. Med. 177:89-97.
43. Zhang, G. H., L. Baek, T. Bertelsen, and C. Koch. 1995. Quantification of the endotoxin-neutralizing capacity of serum and plasma. APMIS 103:721-730.
44. Zhang, G. H., L. Baek, P. E. Nielsen, O. Buchardt, and C. Koch. 1994. Sensitive quantitation of endotoxin by enzyme-linked immunosorbent assay with a monoclonal antibody against Limulus peptide C. J. Clin. Microbiol. 32:416-422.